Table 6:

The Effects of Payments on Prescription of Target versus Rival Drugs

	Dependent Variable: Number of Patients Prescribed:
	Warfarin	Target NOAC
	(1)	(2)
	Payments promoting:
Payment count, by type:	Any NOAC	Target NOAC
Own Compensation	0.0159 (0.0536)	0.3772 (0.1160)
Own Food	0.0104 (0.0030)	0.0577 (0.0037)
Peer Compensation	0.0050 (0.0041)	0.0194 (0.0061)
Peer Food	0.0054 (0.0015)	−0.0006 (0.0013)
		Rival NOACs
Own Compensation		−0.1163 (0.0347)
Own Food		0.0047 (0.0015)
Peer Compensation		−0.0012 (0.0022)
Peer Food		−0.0018 (0.0005)
Mean dependent variable	1.4864	0.5486
N (Doctor × Drug × Quarter)	1,796,544	5,466,420

Notes: Estimates using equation (2) with the dependent variables being the quarterly number of prescribed patients within different segments of the anticoagulant market: warfarin, (the off-patent and unpromoted incumbent) in column 1, and the target NOAC in column 2. The independent variables capture the counts of different types of payments made to the prescribing physicians (“Own”) or to others with whom the prescribing physicians shared patients (“Peers”). See Section 1 for definitions of Food and Compensation. Different panels show payments associated with any NOAC, the target NOAC, and other rival NOACs, as labeled (see Section 4 for details). Physician-drug, specialty-drug-quarter fixed effects, controls for all other types of payments, and payment-type-specific linear time trends included in all specifications. Standard errors are clustered within doctor.